Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) GCK Antibodies:
anti-Rat (Rattus) GCK Antibodies:
anti-Human GCK Antibodies:
Go to our pre-filtered search.
Human Monoclonal GCK Primary Antibody for ELISA, WB - ABIN969172
Barbetti, Cobo-Vuilleumier, Dionisi-Vici, Toni, Ciampalini, Massa, Rodriguez-Bada, Colombo, Lenzi, Garcia-Gimeno, Bermudez-Silva, Rodriguez de Fonseca, Banin, Aledo, Baixeras, Sanz, Cuesta-Muñoz: Opposite clinical phenotypes of glucokinase disease: Description of a novel activating mutation and contiguous inactivating mutations in human glucokinase (GCK) gene. in Molecular endocrinology (Baltimore, Md.) 2009
Show all 2 Pubmed References
Human Monoclonal GCK Primary Antibody for ELISA, WB - ABIN966192
Yoshida, Kato, Yokoi, Oguri, Watanabe, Metoki, Yoshida, Satoh, Aoyagi, Nishigaki, Nozawa, Yamada: Association of genetic variants with chronic kidney disease in individuals with different lipid profiles. in International journal of molecular medicine 2009
Show all 2 Pubmed References
Human Polyclonal GCK Primary Antibody for IF (p), IHC (p) - ABIN734558
Wang, Liu, Chen, Duan, Chen, Xi: Effects of a Novel Glucokinase Activator, HMS5552, on Glucose Metabolism in a Rat Model of Type 2 Diabetes Mellitus. in Journal of diabetes research 2017
Human Polyclonal GCK Primary Antibody for FACS, IF - ABIN411493
Huang, Chou, Lee, Chen, Chen, Tao, Shih: MicroRNA-130a can inhibit hepatitis B virus replication via targeting PGC1α and PPARγ. in RNA (New York, N.Y.) 2015
Cow (Bovine) Polyclonal GCK Primary Antibody for WB - ABIN2788816
Tian, Liu, Wang, Dong, Su, Ma, Zhang: Anti-diabetes effect of chronic intermittent hypobaric hypoxia through improving liver insulin resistance in diabetic rats. in Life sciences 2016
This study using immunoreactive techniques, we have demonstrated in those specific areas of the rainbow trout brain previously described as glucosensor the presence of glucokinase in different cell types.
GKRP (show GCKR Antibodies) binds to a super-open conformation of GK mainly through hydrophobic interaction, inhibiting the GK activity by locking a small domain of GK.
GCK expression is regulated by nutrient-sensing O-linked beta-N-acetylglucosaminylation cycling in liver.
Absence of Gck expression did not prevent the glucose responsiveness of glucose-excited or glucose-inhibited Sf1 (show SF1 Antibodies) neurons in either sex. Thus Gck in the VMN plays a sex-specific role in the glucose-dependent control of autonomic nervous activity; this is, however, unrelated to the control of the firing activity of classical glucose-responsive neurons.
Using a mutant GCK gene (GCK 262) with a knocked out cytosine at position 2643 results in lower protein expression and more ubiquitination-led protein degradation compared with wild-type GCK (GCK 261)
lncLGR facilitates the recruitment of hnRNPL (show HNRNPL Antibodies) to the GCK promoter and suppresses GCK transcription.
Given that acetylated GKRP (show GCKR Antibodies) may affiliate with type-2 diabetes mellitus (T2DM), understanding the mechanism of GKRP (show GCKR Antibodies) acetylation in the liver could reveal novel targets within the GK-GKRP (show GCKR Antibodies) pathway, for treating T2DM and other metabolic pathologies.
These results suggest a mechanism for integrative control over GCK activation and, therefore, glucose metabolism and insulin (show INS Antibodies) secretion through regulation of cytoplasmic Ca(2 (show CA2 Antibodies)+) levels.
GHR (show GHR Antibodies) knockdown caused increased glucokinase mRNA and protein levels.
results suggest that chronic suppression of hepatic glucokinase has a small influence on intertissue (liver-to-BAT (show BAAT Antibodies) as well as liver-to-beta-cell) metabolic communication
Atf3 (show ATF3 Antibodies)-silencing reversed ethanol-mediated Gck down-regulation and beta-cell dysfunction, followed by the amelioration of impaired glucose tolerance and insulin (show INS Antibodies) resistance.
Suggest heterozygous glucokinase knockout mouse as a translatable model of human type 2 diabetes.
GCK GCK GCK GCK
GCK gene mutations (pathogenic or likely pathogenic variants) and a novel intronic variant of uncertain significance (c.208 + 3A>T) were identified in 13/54 probands (24%).
Data suggest that hepatic glucokinase activity is regulated by reversible binding to specific inhibitor protein glucokinase regulatory protein (GKRP (show GCKR Antibodies)) and by binding to activator proteins such as 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase (PFK2 (show PFKFB3 Antibodies)/FBP2 (show KHSRP Antibodies)); changes in glucokinase expression and activity are associated with poorly controlled type 2 diabetes and nonalcoholic fatty liver disease. [REVIEW]
GCK mutations are associated with MODY2.
Glucokinase mutations are associated with Maturity-Onset Diabetes of the Young.
The results show that p.Leu77Arg but not p.Val101Met GCK mutation is considered a pathogenic mutation associated with maturity onset diabetes of the young.
GCK mutations are associated with Maturity onset diabetes of youth.
glucokinase mutation is associated with Maturity-Onset Diabetes of the Young, Type 2.
The number of mutations in GCK/MODY2 or even other MODY (show HNF4A Antibodies)-related genes is undoubtedly underestimated, as accepted criteria for performing genetic tests include family history of the pathology.
Hexokinases phosphorylate glucose to produce glucose-6-phosphate, the first step in most glucose metabolism pathways. Alternative splicing of this gene results in three tissue-specific forms of glucokinase, one found in pancreatic islet beta cells and two found in liver. The protein localizes to the outer membrane of mitochondria. In contrast to other forms of hexokinase, this enzyme is not inhibited by its product glucose-6-phosphate but remains active while glucose is abundant. Mutations in this gene have been associated with non-insulin dependent diabetes mellitus (NIDDM), maturity onset diabetes of the young, type 2 (MODY2) and persistent hyperinsulinemic hypoglycemia of infancy (PHHI).
, hexokinase 4
, HK IV
, hexokinase type IV
, ATP:D-hexose 6-phosphotransferase
, hexokinase D, pancreatic isozyme
, glucokinase (hexokinase 4, maturity onset diabetes of the young 2)
, MAPK/ERK kinase kinase kinase 2
, MEK kinase kinase 2
, MEKKK 2
, RAB8 interacting protein
, germinal center kinase
, mitogen activated protein kinase kinase kinase kinase 2
, rab8-interacting protein